中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

94 records (took 0.03 seconds)

    THERAPEUTIC AGENT FOR CANCER
    22.
    发明公开
    THERAPEUTIC AGENT FOR CANCER 有权
    治疗师WIRKSTOFF GEGEN KREBS

    公开(公告)号：EP1894575A1

    公开(公告)日：2008-03-05

    申请号：EP06766982.0

    申请日：2006-06-20

    Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

    Inventor： MEKADA, Eisuke ,  MIYAMOTO, Shingo

    IPC: A61K45/00 ,  A61K38/00 ,  A61P35/00 ,  A61P35/04

    CPC classification number: A61K38/164

    Abstract: The present invention provides a cancer therapeutic agent containing as an active ingredient a substance, particularly CRM197 which inhibits the binding of HB-EGF to EGF receptor by binding to HB-EGF, wherein a cancer is selected from the group consisting of a bladder cancer, a colon cancer or peritoneal metastatic cancers of a stomach cancer and a pancreatic cancer.

    Abstract translation: 本发明提供一种癌症治疗剂，其含有作为活性成分的物质，特别是CRM197，其通过结合HB-EGF抑制HB-EGF与EGF受体的结合，其中癌症选自膀胱癌， 胃癌和胰腺癌的结肠癌或腹膜转移性癌症。

    MEASLES VIRUS MUTANT ANTIGEN AND GENE ENCODING THE SAME
    25.
    发明授权
    MEASLES VIRUS MUTANT ANTIGEN AND GENE ENCODING THE SAME 失效
    麻疹病毒和基因编码突变体抗原。

    公开(公告)号：EP0949333B1

    公开(公告)日：2006-05-17

    申请号：EP98923127.9

    申请日：1998-06-04

    Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

    Inventor： UEDA, Shigeharu ,  WATANABE, Michiko ,  KAWANISHI, Hitomi

    IPC: C12N15/45 ,  C07K14/115 ,  C07K7/06 ,  A61K39/165 ,  A61K48/00

    CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K2039/51 ,  A61K2039/525 ,  A61K2039/53 ,  C12N2760/18422

    Abstract: Mutant measles virus antigens containing at least one protein antigen selected from the group consisting of (I) mutant measles virus H protein antigens and (II) mutant measles virus F protein antigens as specified below: (I) at least one measles virus H protein antigen selected from the group consisting of a full-length protein of an amino acid sequence consisting of 617 amino acids in total described in SEQ ID NO:2 or 10 and specific peptide fragments thereof, and (II) at least one measles virus F protein antigen selected from the group consisting of a full-length protein of an amino acid sequence consisting of 550 amino acids in total described in SEQ ID NO:18 or 20 and specific peptide fragments thereof; and mutant measles virus genes containing genes encoding the above mutant measles virus antigens. The use of these antigens or genes encoding the same makes it possible to efficiently and economically provide attenuated live measles vaccines or gene vaccines suitable for epidemic measles virus strains and diagnostics for appropriately detecting the infection with epidemic measles virus strains.

    MALARIA PLASMODIUM ANTIGEN POLYPEPTIDE SE36, METHOD OF PURIFYING THE SAME AND VACCINE AND DIAGNOSTIC WITH THE USE OF THE THUS OBTAINED ANTIGEN
    26.
    发明公开
    MALARIA PLASMODIUM ANTIGEN POLYPEPTIDE SE36, METHOD OF PURIFYING THE SAME AND VACCINE AND DIAGNOSTIC WITH THE USE OF THE THUS OBTAINED ANTIGEN 有权
    疟原虫抗原多肽SE36，疫苗和诊断清洁和方法使用如此得到抗原

    公开(公告)号：EP1279735A1

    公开(公告)日：2003-01-29

    申请号：EP02710343.1

    申请日：2002-01-24

    Applicant: The Research Foundation for Microbial Diseases of Osaka University ,  Horii, Toshihiro

    Inventor： HORII, Toshihiro

    IPC: C12N15/30 ,  C07K14/445 ,  C07K1/34 ,  C12P21/02 ,  A61K39/015 ,  A61P33/06 ,  G01N33/569

    CPC classification number: C07K14/445 ,  A61K39/00 ,  Y02A50/412

    Abstract: The present invention provides a polypeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, Plasonodium falciparum , at the erythrocyte stage, a process for purifying said polypeptide, and a malaria vaccine and diagnostic agent using as an active component said purified antigen obtained therefrom. SE36 can be produced in Escherichia coli on a large scale by deleting all or part of polymerized serines of the 47 kd serine-repeat region, whereby high purification is permitted. The human IgG3 antibodies specifically binding to SE36 prevents highly effectively growth of the protozoa in the red blood cells to inhibit fever and cerebral malaria, and further prevent the death.

    Abstract translation: 本发明提供了由疟原虫产生SERA（丝氨酸重复抗原）的从N-末端结构域衍生的（47个KD）的多肽SE36，Plasonodium疟原虫，在红细胞阶段，用于纯化的方法，所述多肽，和疟疾疫苗 并利用从那里得到的所说的纯化抗原作为活性成分的诊断剂。 SE36可以在大肠杆菌中通过删除47 KD丝氨酸重复区，由此高纯化被允许的聚合丝氨酸的全部或部分来制备大规模。 该人IgG3抗体的红细胞特异性结合SE36防止高度有效的原虫生长抑制发热和脑型疟疾，并进一步防止死亡。

    FUNCTIONAL FRAGMENT ANTIGEN OF TETANUS TOXIN AND TETANUS VACCINE
    28.
    发明公开
    FUNCTIONAL FRAGMENT ANTIGEN OF TETANUS TOXIN AND TETANUS VACCINE 失效
    TETANUSVAKZINE的FUNKISELLES抗原抗坏血酸

    公开(公告)号：EP0845270A1

    公开(公告)日：1998-06-03

    申请号：EP97907448.1

    申请日：1997-03-24

    Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

    Inventor： MATSUDA, Morihiro

    IPC: A61K39/08 ,  C12N15/00 ,  C12N15/31 ,  C12P21/02

    CPC classification number: C12P21/02 ,  A61K39/00 ,  C07K14/33

    Abstract: A functional fragment antigen of tetanus toxin characterized in that the antigen comprises a fragment which is substantially the same as at least one type of the fragments obtained by cleaving at least one of the peptide bonds formed between the amino acid residues in the partial amino acid sequence present between the two cysteine residues participating in the disulfide bridge present on the N-terminal side in the full-length amino acid sequence of a full-length tetanus toxin molecule, also cleaving the disulfide bridge itself, and further cleaving the non-covalent bonds between the amino acid residues that constitute the toxin molecule peptide, that it has a molecular weight of 90,000 to 110,000 as determined by SDS-polyacrylamide gel electrophoresis and an isoelectric point of 7.25±0.5 as determined by isoelectric electrophoresis, and that it has an immunogenicity substantially equal to that of a full-length tetanus toxin molecule. This antigen keeps an immunogenicity as a tetanus vaccine antigen and is remarkably reduced in side effects. The invention also provides a process for the mass production of the functional fragment antigen, a vaccine containing this antigen, and a mixed vaccine comprising the above vaccine and a different vaccine.

    Abstract translation: 破伤风毒素的功能性片段抗原，其特征在于所述抗原包含与至少一种类型的片段基本相同的片段，所述片段通过切割部分氨基酸序列中的氨基酸残基之间形成的至少一个肽键而获得 存在于全长破伤风毒素分子的全长氨基酸序列中参与存在于N末端侧的二硫键的两个半胱氨酸残基之间，也切割二硫桥本身，并进一步切割非共价键 在构成毒素分子肽的氨基酸残基之间，其通过SDS-聚丙烯酰胺凝胶电泳测定的分子量为90,000至110,000，通过等电泳测定的等电点为7.25 +/- 0.5，并且其具有 基本上等于全长破伤风毒素分子的免疫原性。 该抗原将免疫原性保持为破伤风疫苗抗原，并且副作用显着降低。 本发明还提供了大规模生产功能性片段抗原，含有该抗原的疫苗以及包含上述疫苗和不同疫苗的混合疫苗的方法。

    Stabilized varicella live vaccine
    29.
    发明公开
    Stabilized varicella live vaccine 失效
    Stabilisierter Lebendimpfstoff。

    公开(公告)号：EP0568726A2

    公开(公告)日：1993-11-10

    申请号：EP92113567.9

    申请日：1992-08-08

    Applicant: The Research Foundation for Microbial Diseases of Osaka University

    Inventor： Koyama, Kuniaki ,  Osame, Juichiro

    IPC: A61K39/25 ,  A61K39/295

    CPC classification number: A61K39/25 ,  A61K39/0015 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/70 ,  C12N2710/16734 ,  Y02A50/39

    Abstract: Disclosed is a stabilized live vaccine containing a varicella virus and a stabilizer, wherein the vaccine is substantially free of Ca²⁺ ions and Mg²⁺ ions. This stabilized live vaccine is extremely excellent in storage stability and heat resistance. Also disclosed is an improved stabilizer for a live varicella vaccine, comprising at least one member selected from gelatin and hydrolyzed gelatin, each being substantially free of Ca²⁺ ions and Mg²⁺ ions. The stabilizer can advantageously be used to stabilize a live vaccine containing a varicella virus. The substantial freedom of Ca²⁺ ions and Mg²⁺ ions can be attained by masking Ca²⁺ ions and Mg²⁺ ions present in a live vaccine containing a varicella virus and a stabilizer, with a chelating reagent, or by using as a stabilizer gelatin and/or a gelatin derivative after being purified to remove Ca²⁺ ions and/or Mg²⁺ ions contained therein.

    Abstract translation: 公开了含有水痘病毒和稳定剂的稳定的活疫苗，其中疫苗基本上不含Ca 2+离子和Mg 2+离子。 这种稳定的活疫苗在储存稳定性和耐热性方面非常优异。 还公开了一种用于活水痘疫苗的改进的稳定剂，其包含至少一种选自明胶和水解明胶的成分，各自基本上不含Ca 2+离子和Mg 2+离子。 稳定剂可有利地用于稳定含有水痘病毒的活疫苗。 Ca 2+离子和Mg 2+离子的实质自由度可以通过掩盖存在于含有活性疫苗的活疫苗中的Ca 2+离子和Mg 2+离子来实现 水解ella病毒和稳定剂，螯合剂，或纯化后用作稳定剂明胶和/或明胶衍生物，以除去其中所含的Ca 2+离子和/或Mg 2+离子 。

    Non-A, non-B hepatitis virus particles
    30.
    发明公开
    Non-A, non-B hepatitis virus particles 失效
    非乙型肝炎病毒-Telchen。

    公开(公告)号：EP0463848A2

    公开(公告)日：1992-01-02

    申请号：EP91305717.0

    申请日：1991-06-25

    Applicant: The Research Foundation for Microbial Diseases of Osaka University

    Inventor： Okayama, Hiroto ,  Fuke, Isao ,  Mori, Chisato ,  Takamizawa, Akihisa ,  Yoshida, Iwao

    IPC: C12N15/40 ,  C12Q1/70 ,  A61K39/29 ,  C07K15/00 ,  G01N33/569

    CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N2770/24222

    Abstract: Disclosed are an isolated non-A, non-B hepatitis virus particle comprising at least one antigen selected from the group consisting of a core antigen, a matrix antigen and an envelope antigen of the non-A, non-B hepatitis virus and a method for efficiently producing the same by genetic engineering. The non-A, non-B hepatitis virus particle can advantageously be used not only for the production of an NANBV hepatitis vaccine exhibiting an extremely high immunogenicity and a diagnostic agent which is extremely high in the antibody detection ratio and in the degree of accuracy of the detection, but is also useful for researches on liver diseases, such as liver cancer.

    Abstract translation: 公开了一种分离的非A非乙型肝炎病毒颗粒，其包含至少一种选自非A非乙型肝炎病毒的核心抗原，基质抗原和包膜抗原的抗原，以及方法 通过基因工程有效地生产。 非A非乙型肝炎病毒颗粒不仅可有利地用于生产显示出非常高的免疫原性的NANBV肝炎疫苗和诊断剂，其具有极高的抗体检测率和精确度 检测，但也适用于肝脏疾病如肝癌的研究。

Patent Agency Ranking